Search clinical trials for: GSK2251052

Total 7 results

GlaxoSmithKline

Terminated

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

Community-acquired Infection

United States
GlaxoSmithKline

Completed

An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects

Community-acquired Infection

United States
GlaxoSmithKline

Completed

A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects

Infections, Bacterial

Australia
GlaxoSmithKline

Completed

GSK2251052 Mass Balance in Healthy Adult Subjects

Community-acquired Infection

Netherlands
GlaxoSmithKline

Terminated

A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study (Relative Bio)

Community-acquired Infection

Australia
GlaxoSmithKline

Terminated

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Infections, Intestinal

United States, Czechia, Russian Federation, Spain, Canada, France, Italy
GlaxoSmithKline

Terminated

GSK2251052 in Complicated Urinary Tract Infection

Infections, Urinary Tract

France, United States, Russian Federation, Spain, Greece, Canada

3

Subscribe